Delphine Mollon

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma

Ronan Abgral, Pierre‐Yves Le Roux, Nathalie Keromnes et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2012 · 40 citations

Medicine, Nuclear Medicine, Oncology +14

Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial

Hervé Bonnefoi, Florence Lerebours, Marina Pulido et al. · The Lancet Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16